Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
PRKAG2 and stroke are reported together in 1 article.
Gene
PRKAG2
- HGNC
- HGNC:9386
3articles
3mentions
0variants with confirmed gene link
Most co-reported phenotypes (articles)
Phenotype
Stroke
555articles
555mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
1 records shown · first 60New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.
PMID 42394189 | DOI 10.1002/jcph.70236 · Journal of clinical pharmacology · 2026 · 11 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PRKAG2 | “A preliminary effect of polymorphisms in CYP2C19, PRF1, and PRKAG2 on rivaroxaban outcome still needs validation.” | 0.98 | hgnc_dict_v1 |
| phenotype | stroke | “Thromboembolic diseases, including venous thromboembolism and atrial fibrillation-related stroke, represent a prevalent health concern and a risk for mortality and health care costs.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CYP3A4 | “CYP3A4 and CYP3A5 polymorphisms greatly impacted the pharmacokinetics of rivaroxaban; CYP2J2 polymorphisms were not greatly associated with the clinical outcome.” | 0.98 | hgnc_dict_v1 |
| gene | CYP3A5 | “CYP3A4 and CYP3A5 polymorphisms greatly impacted the pharmacokinetics of rivaroxaban; CYP2J2 polymorphisms were not greatly associated with the clinical outcome.” | 0.98 | hgnc_dict_v1 |